Breaking News

Ophthotech initiates Fovista expansion trials

The first of three planned expansion trials has been initiated for Fovista, according to an Ophthotech press release.

Researchers will examine the antiplatelet-derived growth factor (anti-PDGF; Fovista, Ophthotech) combination therapy as a potential treatment for sub-retinal fibrosis reduction and treatment responses. They will also investigate whether the therapy provides reductions to treatment burden among patients with wet age-related macular degeneration who are receiving anti-VEGF monotherapy, according to the release.

The phase 2a open-label study will investigate the role of anti-PDGF therapy combined with anti-VEGF in an effort to reduce subretinal fibrosis in patients with AMD.

Up to 1,866 patients are expected to be enrolled in the three trials at more than 225 centers worldwide.

Topline data from the Fovista combination therapy phase 3 clinical program currently underway are expected in 2016, according to the release.

The first of three planned expansion trials has been initiated for Fovista, according to an Ophthotech press release.

Researchers will examine the antiplatelet-derived growth factor (anti-PDGF; Fovista, Ophthotech) combination therapy as a potential treatment for sub-retinal fibrosis reduction and treatment responses. They will also investigate whether the therapy provides reductions to treatment burden among patients with wet age-related macular degeneration who are receiving anti-VEGF monotherapy, according to the release.

The phase 2a open-label study will investigate the role of anti-PDGF therapy combined with anti-VEGF in an effort to reduce subretinal fibrosis in patients with AMD.

Up to 1,866 patients are expected to be enrolled in the three trials at more than 225 centers worldwide.

Topline data from the Fovista combination therapy phase 3 clinical program currently underway are expected in 2016, according to the release.